💊 Zydus Lifesciences Falls Despite Major USFDA Approval

shares declined over 1% on December 24, 2025, even after announcing a significant positive development. The company’s UAE-based subsidiary entered into a strategic partnership with Swiss biopharmaceutical firm Bioeq to license and commercialize Nufymco in the US market. Nufymco is a VEGF inhibitor and an interchangeable biosimilar of Lucentis (Ranibizumab). Adding to the positive momentum, the Biologics License Application for Nufymco received USFDA approval on December 18. However, the stock’s decline suggests short-term market caution despite strong long-term growth prospects.